BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31019975)

  • 1. Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
    Wang W; Hu Z; Huang Y; Zheng H; Sun Q; Yang Q; Zhang Y; Zhang L; Wang W
    Biomed Res Int; 2019; 2019():9205851. PubMed ID: 31019975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic implication of HER2 in advanced biliary tract cancer.
    Nam AR; Kim JW; Cha Y; Ha H; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Oncotarget; 2016 Sep; 7(36):58007-58021. PubMed ID: 27517322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
    Yu Y; Wang J; Xia N; Li B; Jiang X
    Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
    Shi Y; Fan Y; Hu Y; Jing J; Wang C; Wu Y; Geng Q; Dong X; Li E; Dong D
    J Cell Mol Med; 2020 Jan; 24(1):760-771. PubMed ID: 31762191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
    Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer.
    Wang FT; Wang H; Wang QW; Pan MS; Li XP; Sun W; Fan YZ
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):221-232. PubMed ID: 32654071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics.
    Hong Y; Abudukeremu X; She F; Chen Y
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23733. PubMed ID: 38770938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
    Gao H; Xie J; Peng J; Han Y; Jiang Q; Han M; Wang C
    Exp Cell Res; 2015 Mar; 332(2):236-46. PubMed ID: 25499970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
    BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
    Zhang DC; Liu JL; Ding YB; Xia JG; Chen GY
    Acta Pharmacol Sin; 2013 Feb; 34(2):301-8. PubMed ID: 23274410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
    Mita Y; Ajiki T; Kamigaki T; Okazaki T; Hori H; Horiuchi H; Hirata K; Fujita T; Fujimori T; Kuroda Y
    Ann Surg Oncol; 2007 Apr; 14(4):1374-80. PubMed ID: 17235714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
    Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
    J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma.
    Ye M; Lv J; Xu G; Wang W; Jing Y; Sun A; Lu Z; Wu X; Liu Y; Shao YW; Liu F; Tao F
    J Int Med Res; 2019 Jun; 47(6):2768-2777. PubMed ID: 31106632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
    Tanizaki J; Okamoto I; Takezawa K; Tsukioka S; Uchida J; Kiniwa M; Fukuoka M; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1198-207. PubMed ID: 20424000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.
    Wang L; Li X; Cheng Y; Yang J; Liu S; Ma T; Luo L; Hu Y; Cai Y; Yan D
    Front Immunol; 2021; 12():784861. PubMed ID: 35069555
    [No Abstract]   [Full Text] [Related]  

  • 17. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
    Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Nagasaki E; Homma S
    BMC Cancer; 2015 Oct; 15():726. PubMed ID: 26475267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
    Xu S; Jiang C; Lin R; Wang X; Hu X; Chen W; Chen X; Chen T
    J Exp Clin Cancer Res; 2021 Nov; 40(1):373. PubMed ID: 34823564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
    Zhan M; Yang RM; Wang H; He M; Chen W; Xu SW; Yang LH; Liu Q; Long MM; Wang J
    Cancer Commun (Lond); 2018 Jul; 38(1):48. PubMed ID: 30016995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.